# Nagi Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nagi-bioscience

- Industry: Biotechnology
- Headquarters: Ecublens, Switzerland
- Website: www.nagibio.ch
- Total disclosed funding: $16M
- Latest round: Series A (Jul 17, 2023)
- Investors on record: 7

## About

Nagi Bioscience SA, located in Ecublens, Switzerland, specializes in high-content biological testing solutions using innovative automated systems for drug and chemical assessment, enhancing research precision and ethical practices.Founded in 2019, Nagi Bioscience SA is focused on developing advanced biological testing technologies. The company has successfully completed three funding deals, with the most recent being a Series A round in July 2023, raising CHF 12.4 million. The firm is led by Matteo Cornaglia, who also serves as the CEO.Nagi Bioscience specializes in high-content biological testing solutions, primarily through its flagship product, the SydLab™ One platform. This fully automated screening platform utilizes C. elegans nematodes to assess the effects of drugs and chemicals, enabling faster and more ethical biological testing. The platform is designed to enhance precision and reproducibility in research, making it particularly valuable for sectors focused on aging, neurodegenerative diseases, and safety toxicology. Nagi Bioscience serves a diverse clientele, including biopharma companies, academic institutions, and research organizations across Europe, North America, and Asia, facilitating advancements in fundamental research, candidate discovery, and toxicology with tailored contract laboratory solutions.Nagi Bioscience operates primarily on a B2B model, generating revenue through partnerships and contract laboratory services. Clients, including pharmaceutical and biotechnology firms, engage with Nagi to access the SydLab™ One platform and its associated services, which include custom studies and high-throughput data generation. The transaction structure typically involves direct agreements with clients for the use of the platform on a project basis or through recurring contracts for ongoing research needs. The company's services are tailored to meet the unique requirements of each client, ensuring detailed and reproducible results that drive their research forward.In July 2023, Nagi Bioscience SA raised CHF 12.4 million in Series A funding co-led by Swisscanto and imec.xpand, with participation from Excellis Holding, Verve Ventures, and Zürcher Kantonalbank. The funding will be utilized to scale manufacturing, grow its team, and support product development and international expansion. The company is focused on launching new products and expanding into targeted markets within Europe and North America by 2024.

## Funding rounds

- Series A, Jul 17, 2023, $14M — Zürcher Kantonalbank, Imec.xpand, Swisscanto, Verve Ventures, Excellis Holding
- Seed, Dec 20, 2019, $1.8M — Zürcher Kantonalbank, investiere, Nest Collective Foundation

## Investors

- Zürcher Kantonalbank — Seed, Series A
- investiere — Seed
- Nest Collective Foundation (https://capitalatlas.ai/funds/nest-collective-foundation) — Seed
- Imec.xpand (https://capitalatlas.ai/funds/imec-xpand) — Series A
- Swisscanto (https://capitalatlas.ai/funds/swisscanto) — Series A
- Verve Ventures (https://capitalatlas.ai/funds/verve-ventures) — Series A
- Excellis Holding — Series A